Assessing toxicities of curative radiotherapy combined with concomitant non anti-cancer drugs: A sub-analysis of the prospective epidemiological RIT trial.
Non-anticancer drugs
Radiotherapy
Side effect
Toxicity
Journal
Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
ISSN: 1879-0887
Titre abrégé: Radiother Oncol
Pays: Ireland
ID NLM: 8407192
Informations de publication
Date de publication:
03 2022
03 2022
Historique:
received:
28
06
2021
revised:
10
01
2022
accepted:
10
01
2022
pubmed:
24
1
2022
medline:
8
4
2022
entrez:
23
1
2022
Statut:
ppublish
Résumé
Limited data are available about non-anticancer treatment (NACTs)/radiation combinations. MORSE 02-17 was the first study to report on the interaction resulting from such combinations in a heterogeneous population. Therefore, the aim of this study was to describe acute and late toxicities in a homogenous cohort of cancer patients receiving NACTs and undergoing radiation therapy. An analysis of the RIT (Radiation Impact on Thromboembolic events) prospective trial was carried-out. Patients with non-metastatic solid tumors and treated with radiotherapy and/or brachytherapy in a curative intent between 2016 and 2019 were included. Data about NACTs and toxicities were then collected. Out of 382 patients, 293 were prescribed NACTs (76.7%) with a median number of 3.6 (range: 1-14) NACTs per patient. Among1006 NACTs, the most prescribed drugs were anti-hypertensive, in 153 patients (52.2%). In accordance with MORSE 02-17 data, four of the main side effects of radiotherapy were analysed: genitourinary, gastrointestinal, dermatitis/mucositis and fatigue. Regarding acute and late toxicities -whatever the grade- no statistical difference was found between NACTs classes and these toxicities. When we compared the rates of toxicities with literature data, NACTs did not seem to have a worsening effect. One could conclude that NACTs concomitantly given with RT do not influence toxicity outcome. We then advocate a development of new platform for toxicity profile investigation of drugs-RT combination.
Sections du résumé
BACKGROUND AND PURPOSE
Limited data are available about non-anticancer treatment (NACTs)/radiation combinations. MORSE 02-17 was the first study to report on the interaction resulting from such combinations in a heterogeneous population. Therefore, the aim of this study was to describe acute and late toxicities in a homogenous cohort of cancer patients receiving NACTs and undergoing radiation therapy.
MATERIAL AND METHODS
An analysis of the RIT (Radiation Impact on Thromboembolic events) prospective trial was carried-out. Patients with non-metastatic solid tumors and treated with radiotherapy and/or brachytherapy in a curative intent between 2016 and 2019 were included. Data about NACTs and toxicities were then collected.
RESULTS
Out of 382 patients, 293 were prescribed NACTs (76.7%) with a median number of 3.6 (range: 1-14) NACTs per patient. Among1006 NACTs, the most prescribed drugs were anti-hypertensive, in 153 patients (52.2%). In accordance with MORSE 02-17 data, four of the main side effects of radiotherapy were analysed: genitourinary, gastrointestinal, dermatitis/mucositis and fatigue. Regarding acute and late toxicities -whatever the grade- no statistical difference was found between NACTs classes and these toxicities.
CONCLUSION
When we compared the rates of toxicities with literature data, NACTs did not seem to have a worsening effect. One could conclude that NACTs concomitantly given with RT do not influence toxicity outcome. We then advocate a development of new platform for toxicity profile investigation of drugs-RT combination.
Identifiants
pubmed: 35065997
pii: S0167-8140(22)00016-0
doi: 10.1016/j.radonc.2022.01.012
pii:
doi:
Substances chimiques
Antineoplastic Agents
0
Types de publication
Clinical Trial
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
23-27Informations de copyright
Copyright © 2022 Elsevier B.V. All rights reserved.